Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing
Even Some Struggling Firms Manage To Float Offerings
Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.
